The Heart Research Institute (HRI) is at the forefront of pioneering research dedicated to preventing, detecting, and treating prevalent heart conditions and cardiovascular disease (CVD). Our comprehensive approach tackles these critical health challenges from diverse and innovative perspectives.
One of our key areas of focus is atherosclerosis. The Atherosclerosis and Vascular Remodelling Group delves into the intricate genetic and molecular mechanisms driving plaque build-up in arteries. By unraveling these pathways, we aim to develop more effective treatments to combat atherosclerotic plaque, a major contributor to heart disease.
The Cardiovascular-protective Signalling and Drug Discovery Group is actively exploring the potential of drug repurposing for next-generation cardiovascular therapies. This innovative approach seeks to identify existing medications that can be adapted to treat heart diseases more effectively, accelerating the development of new treatment options.
Our Clinical Research Group is dedicated to improving the lives of individuals with congenital heart disease (CHD), particularly young adults. Their research encompasses projects designed to enhance quality of life and exercise capacity for those living with CHD, improve health outcomes for young adults and their families, and maintain the National Congenital Heart Disease Registry.
The Coronary Diseases Group is investigating the anti-inflammatory drug colchicine as a potential protective agent against recurrent heart attacks. Building on colchicine’s established safety and efficacy in treating conditions like arthritis and gout, this research explores its potential to prevent further cardiac events in heart attack survivors.
Addressing the growing concern of stroke, the Heart Rhythm and Stroke Prevention Group is focused on optimizing large-scale screening for atrial fibrillation (AF). Given AF’s link to a significant proportion of strokes, this research aims to implement effective screening strategies to prevent stroke and improve public health outcomes.
The Vascular Complications Group is dedicated to understanding the development of blood vessel disease in individuals with diabetes. By elucidating the underlying mechanisms, they seek to identify novel strategies to improve vascular function and reduce the disease burden associated with diabetes-related cardiovascular complications.
Finally, the Vascular Immunology Group is concentrating on gaining a deeper understanding of preeclampsia and its long-term effects, as well as developing new drug treatments for this pregnancy-related condition. Preventing preeclampsia is crucial not only for maternal health but also for reducing the future risk of CVD in women.
Through these diverse yet interconnected research initiatives, the HRI is committed to making significant strides in Common Cardiology Diagnosis, treatment, and prevention, ultimately working towards a healthier future for all hearts.
